Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
iTeos Therapeutics, Inc. (ITOS)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/12/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/25/2023 |
4
| Boxer Capital, LLC (See remarks) has filed a Form 4 on iTeos Therapeutics, Inc.|
Txns:
| Sold 34,846 shares
@ $14.19, valued at
$494.5k
Sold 95,516 shares
@ $15.63, valued at
$1.5M
Sold 219,638 shares
@ $16.87, valued at
$3.7M
|
|
| 08/23/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 06/15/2023 |
4
| Van Hauwermeiren Timothy (Director) has filed a Form 4 on iTeos Therapeutics, Inc.|
Txns:
| Granted 22,383 options to buy
@ $14.77, valued at
$330.6k
|
|
| 06/15/2023 |
4
| RHOADS ANN D (Director) has filed a Form 4 on iTeos Therapeutics, Inc.|
Txns:
| Granted 22,383 options to buy
@ $14.77, valued at
$330.6k
|
|
| 06/15/2023 |
4
| Iannone Robert (Director) has filed a Form 4 on iTeos Therapeutics, Inc.|
Txns:
| Granted 22,383 options to buy
@ $14.77, valued at
$330.6k
|
|
| 06/15/2023 |
4
| Ho Tony W (Director) has filed a Form 4 on iTeos Therapeutics, Inc.|
Txns:
| Granted 22,383 options to buy
@ $14.77, valued at
$330.6k
|
|
| 06/15/2023 |
4
| Hallal David (Director) has filed a Form 4 on iTeos Therapeutics, Inc.|
Txns:
| Granted 22,383 options to buy
@ $14.77, valued at
$330.6k
|
|
| 06/15/2023 |
4
| DiRocco Derek (Director) has filed a Form 4 on iTeos Therapeutics, Inc.|
Txns:
| Granted 22,383 options to buy
@ $14.77, valued at
$330.6k
|
|
| 06/15/2023 |
4
| Davis Aaron I. (Director) has filed a Form 4 on iTeos Therapeutics, Inc.|
Txns:
| Granted 22,383 options to buy
@ $14.77, valued at
$330.6k
|
|
| 05/19/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/10/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/29/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/15/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/15/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/10/2023 |
4
| McGrath Yvonne (Chief Scientific Officer) has filed a Form 4 on iTeos Therapeutics, Inc.|
Txns:
| Granted 130,000 options to buy
@ $16.66, valued at
$2.2M
|
|
| 03/10/2023 |
4
| Lager Joanne Jenkins (Chief Medical Officer) has filed a Form 4 on iTeos Therapeutics, Inc.|
Txns:
| Granted 130,000 options to buy
@ $16.66, valued at
$2.2M
|
|
| 03/10/2023 |
4
| Gall Matthew (CFO) has filed a Form 4 on iTeos Therapeutics, Inc.|
Txns:
| Granted 130,000 options to buy
@ $16.66, valued at
$2.2M
|
|
| 03/10/2023 |
4
| Call Matthew (COO) has filed a Form 4 on iTeos Therapeutics, Inc.|
Txns:
| Granted 130,000 options to buy
@ $16.66, valued at
$2.2M
|
|
| 03/10/2023 |
4
| Detheux Michel (CEO) has filed a Form 4 on iTeos Therapeutics, Inc.|
Txns:
| Granted 346,000 options to buy
@ $16.66, valued at
$5.8M
Gifted 254,997 options to buy
@ $16.66, valued at
$4.2M
Gifted 254,997 options to buy
@ $16.66, valued at
$4.2M
|
|
| 03/10/2023 |
5
| Detheux Michel (CEO) has filed a Form 5 on iTeos Therapeutics, Inc. |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G
| VANGUARD GROUP INC reports a 5.1% stake in iTeos Therapeutics Inc. |
| 02/03/2023 |
8-K
| Quarterly results |
| 01/09/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 08/10/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/08/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
|
|
|